PURPOSE: There is preliminary evidence for prostate-specific membrane antigen (PSMA) upregulation effects of androgen receptor blockade in prostate cancer. In an attempt to find the best condition for PSMA radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC) patients, we evaluated the effect of oral enzalutamide in patients, predominantly having previously progressed on enzalutamide treatment. METHODS: Ten patients with advanced mCRPC scheduled for PSMA radioligand therapy were examined with 68Ga-PSMA-11 PET/CT before and after a mean of 11.8 days of enzalutamide 160 mg/day. Imaging results were compared using total PSMA tumor burden quantification. We assessed whole-body total lesion PSMA (TLP), defined as SUVmean × tumor volume and calculated TLP-to-liver ratio (TLP-LR), TLP-to-parotid gland ratio (TLP-PR), and TLP-to-kidney ratio (TLP-KR). RESULTS: The mean (median) increase of TLP-LR, TLP-PR, and TLP-KR in the cohort was 49.3% (38.8%), 45.1% (23.5%), and 54.9% (37.6%), respectively. These increases were statistically significant (p = 0.002, p = 0.014, and p = 0.014), while PSA values did not change significantly (p = 0.846). Seven of the 10 patients had previously undergone enzalutamide treatment with eventual progression, formally classified as treatment failure. No side effects were noted in the short term. CONCLUSIONS: Our results suggest that enzalutamide could be considered as a PSMA radioligand treatment enhancing primer medication, which may increase PSMA expression by a dimension of 50% in mCRPC. The effect was shown even in patients having previously failed enzalutamide treatment for arrest of progression in the mCRPC setting. Our observation deserves evaluation in a prospective setting.
PURPOSE: There is preliminary evidence for prostate-specific membrane antigen (PSMA) upregulation effects of androgen receptor blockade in prostate cancer. In an attempt to find the best condition for PSMA radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC) patients, we evaluated the effect of oral enzalutamide in patients, predominantly having previously progressed on enzalutamide treatment. METHODS: Ten patients with advanced mCRPC scheduled for PSMA radioligand therapy were examined with 68Ga-PSMA-11 PET/CT before and after a mean of 11.8 days of enzalutamide 160 mg/day. Imaging results were compared using total PSMAtumor burden quantification. We assessed whole-body total lesion PSMA (TLP), defined as SUVmean × tumor volume and calculated TLP-to-liver ratio (TLP-LR), TLP-to-parotid gland ratio (TLP-PR), and TLP-to-kidney ratio (TLP-KR). RESULTS: The mean (median) increase of TLP-LR, TLP-PR, and TLP-KR in the cohort was 49.3% (38.8%), 45.1% (23.5%), and 54.9% (37.6%), respectively. These increases were statistically significant (p = 0.002, p = 0.014, and p = 0.014), while PSA values did not change significantly (p = 0.846). Seven of the 10 patients had previously undergone enzalutamide treatment with eventual progression, formally classified as treatment failure. No side effects were noted in the short term. CONCLUSIONS: Our results suggest that enzalutamide could be considered as a PSMA radioligand treatment enhancing primer medication, which may increase PSMA expression by a dimension of 50% in mCRPC. The effect was shown even in patients having previously failed enzalutamide treatment for arrest of progression in the mCRPC setting. Our observation deserves evaluation in a prospective setting.
Authors: Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Sarah M Schwarzenboeck; Isabel Rauscher; Christina Bluemel; Wolfgang P Fendler; Steven P Rowe; Martin G Pomper; Ali Afshar-Oromieh; Ken Herrmann; Matthias Eiber Journal: J Nucl Med Date: 2017-07-07 Impact factor: 10.057
Authors: Ali Afshar-Oromieh; John W Babich; Clemens Kratochwil; Frederik L Giesel; Michael Eisenhut; Klaus Kopka; Uwe Haberkorn Journal: J Nucl Med Date: 2016-10 Impact factor: 10.057
Authors: M Kuriyama; M C Wang; C I Lee; L D Papsidero; C S Killian; H Inaji; N H Slack; T Nishiura; G P Murphy; T M Chu Journal: Cancer Res Date: 1981-10 Impact factor: 12.701
Authors: Wolfgang P Fendler; Svenja Reinhardt; Harun Ilhan; Andreas Delker; Guido Böning; Franz J Gildehaus; Christian Stief; Peter Bartenstein; Christian Gratzke; Sebastian Lehner; Axel Rominger Journal: Oncotarget Date: 2017-01-10
Authors: Darren R Veach; Claire M Storey; Katharina Lückerath; Katharina Braun; Christian von Bodman; Urpo Lamminmäki; Teja Kalidindi; Sven-Erik Strand; Joanna Strand; Mohamed Altai; Robert Damoiseaux; Pat Zanzonico; Nadia Benabdallah; Dmitry Pankov; Howard I Scher; Peter Scardino; Steven M Larson; Hans Lilja; Michael R McDevitt; Daniel L J Thorek; David Ulmert Journal: Clin Cancer Res Date: 2021-01-13 Impact factor: 12.531
Authors: Stefanie Zschäbitz; Franziska Erlmeier; Christine Stöhr; Edwin Herrmann; Iris Polifka; Abbas Agaimy; Lutz Trojan; Philipp Ströbel; Frank Becker; Christian Wülfing; Peter Barth; Michael Stöckle; Michael Staehler; Christian Stief; Axel Haferkamp; Markus Hohenfellner; Stephan Macher-Göppinger; Bernd Wullich; Joachim Noldus; Walburgis Brenner; Frederik C Roos; Bernhard Walter; Wolfgang Otto; Maximilian Burger; Andres Jan Schrader; Yvonne Mondorf; Arndt Hartmann; Philipp Ivanyi; Sandra Steffens Journal: J Cancer Date: 2022-03-14 Impact factor: 4.207
Authors: Saskia Fassbind; Daniela A Ferraro; Jean-Jacques Stelmes; Christian D Fankhauser; Matthias Guckenberger; Philipp A Kaufmann; Daniel Eberli; Irene A Burger; Benedikt Kranzbühler Journal: Ann Nucl Med Date: 2021-06-29 Impact factor: 2.668